AI assistant
Sending…
Niagen Bioscience, Inc. — Director's Dealing 2020
Apr 1, 2020
32418_dirs_2020-03-31_ae595463-bdf1-49f3-88cd-d2c7c2132861.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2020-03-27
Reporting Person: Jordan Megan Kern (N/A)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (right to buy) | $4.12 | 2029-04-02 | Common Stock (30000) | Direct | |
| Stock Options (right to buy) | $4.47 | 2029-08-06 | Common Stock (320000) | Direct | |
| Stock Options (right to buy) | $4.18 | 2030-01-27 | Common Stock (150000) | Direct |
Footnotes
F1: Options vested 100% on October 2, 2019
F2: Options vest 33% on August 6, 2020 and thereafter 1/36th vest each month.
F3: Options vest 33% on January 27, 2021 and thereafter 1/36th vest each month.
More from Niagen Bioscience, Inc.
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Mar 19
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24
Major Shareholding Notification
2026
Jan 30
Regulatory Filings
2025
Dec 22
Director's Dealing
2025
Nov 17
Regulatory Filings
2025
Nov 6